Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

The European Medicines Agency (EMA) announced on July 7, 2026 that it has opened a phased review of daraxonrasib, an investigational treatment for metastatic pancreatic cancer, marking one of the earliest tests of an accelerated assessment model expected to expand under the European Union's pharmaceutical legislation reform.¹

The EMA’s Committee for Medicinal Products for Human Use began evaluating data on daraxonrasib following results from a phase 3 study comparing the therapy with chemotherapy in patients whose metastatic pancreatic cancer had progressed after prior treatment.¹ Rather than waiting for a complete marketing authorization application, the committee will review quality, nonclinical, and clinical data in stages as each becomes available.

Why Does This Patient Population Warrant Expedited Review?

Patients with metastatic pancreatic cancer whose disease has progressed after initial treatment face a median life expectancy of roughly 6 months, with few therapeutic options remaining.¹ That unmet need is what qualified daraxonrasib for high-priority status under the EMA’s Cancer Medicines Pathfinder project, a designation that expedited its eligibility for a centralized marketing authorization application and, in turn, opened the door to phased review.

Importantly, the agency has emphasized that medicines evaluated through this pathway are held to identical standards for quality, safety, and efficacy as those reviewed through conventional timelines.¹ The acceleration applies to the sequencing of assessment work, not to the evidentiary bar a therapy must clear.

What Does This Mean for Development and Manufacturing?

The daraxonrasib review offers a preview of how phased assessment could reshape submission planning under the EU’s pharmaceutical legislation reform, which is expected to strengthen and formalize this approach going forward.¹

Under a phased review, quality and manufacturing data can be scrutinized well ahead of a complete application submission, rather than as part of a single consolidated dossier.¹ That shift has direct implications for how sponsors sequence their internal readiness: manufacturing data packages, stability data, and process validation documentation may need to be finalized and submission-ready earlier in a program's lifecycle than has traditionally been the case. Companies pursuing centralized marketing authorization for high-unmet-need therapies should anticipate that regulatory engagement, and the internal cross-functional coordination it demands could begin well before a full application is otherwise assembled.

The agency has not projected a specific timeline for completing the daraxonrasib review, noting only that the process is expected to be shorter than a standard evaluation because a portion of the assessment occurs before the full application arrives.¹ That uncertainty itself is instructive, sponsors considering this pathway should recognize that phased review compresses overall timelines by parallelizing work, not by relaxing any single component of the assessment.

The EMA indicated it will continue evaluating other medicines in development for phased review on a case-by-case basis, weighing whether a therapy addresses significant unmet medical need and holds major public health relevance, particularly where therapeutic innovation is concerned.¹

How Does the Broader EU Pharma Package Shape This Precedent?

The daraxonrasib review does not exist in isolation, it arrives as part of a far larger legislative overhaul: a new Regulation and Directive that will replace the two-decade-old framework governing medicine authorization across the EU.²

Among the most consequential changes for development teams is the shortened scientific assessment timeline built into the reform.² Centralized marketing authorization applications will generally move through review in 180 days rather than the current 210, with medicines judged to be of major public health interest eligible for a further reduction to 150 days. That compressed standard timeline, layered alongside the phased review approach being tested with daraxonrasib, signals a broader institutional shift toward evaluating high-priority therapies earlier and in parallel rather than sequentially.

The practical implications extend beyond oncology.² Companies developing therapies for orphan conditions, unmet medical needs, or other priority categories should expect regulatory engagement, and the internal readiness it demands, to begin well before a complete application is traditionally assembled. As reformed pharmaceutical legislation moves forward, compressed review timelines are positioned to become a more routine option rather than an exception.

References

1. EMA fast tracks review of a medicine for metastatic pancreatic cancer. European Medicines Agency. Press Release. July 7, 2026. https://www.ema.europa.eu/en/news/ema-fast-tracks-review-medicine-metastatic-pancreatic-cancer
2. The EU pharma package finally here: what it changes and what it means. HSF Kramer. April 2026. https://www.hsfkramer.com/en_US/notes/ip/2026-04/the-eu-pharma-package-finally-here-what-it-changes-and-what-it-means